However, when combined with an A2A adenosine receptor antagonist, MTA therapy does result in neuroprotection, which is particularly significant given that A2A adenosine receptor antagonists are currently being assessed in clinical trials for the symptomatic treatment of PD and the prevention of L-DOPA-induced dyskinesias. The gene discussed is ADORA2A; the disease is Dyskinesia.